We are live on ! Find out more
ATXI icon

Avenue Therapeutics

Delisted

ATXI was delisted on the 18th of March, 2025.

7 hedge funds and large institutions have $624K invested in Avenue Therapeutics in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

0% less ownership

Funds ownership: 2.09% → 2.09% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

14% less capital inflows, than outflows

Capital inflows: $12.3K | Capital outflows: $14.3K

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ATXI Hedge Fund Activity: Q3 2018 in Review

7 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics (ATXI) for Q3 2018, worth a combined $624K — down 21% from $789K a quarter earlier.

Fund positioning in ATXI was balanced in Q3 2018: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was B. Riley Wealth Advisors, adding an estimated $8.22K. The largest seller was UBS Group, cutting an estimated $8.22K.

  • 7 institutional investors held Avenue Therapeutics (ATXI) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $624K of Avenue Therapeutics stock for Q3 2018, down 21% quarter-over-quarter.
  • 1 fund opened new Avenue Therapeutics positions in Q3 2018 and 1 closed out, a net change of 0 holders.
  • The largest Avenue Therapeutics buyer in Q3 2018 was B. Riley Wealth Advisors, an estimated $8.22K added.
  • The largest Avenue Therapeutics seller in Q3 2018 was UBS Group, an estimated $8.22K sold.

Based on aggregated 13F filings for Q3 2018.